OPK

OPKO Health, Inc. 2008 Annual Report (10-K) Summary

Business Context and Reporting Period

This report covers the fiscal year ended December 31, 2008. OPKO Health, Inc. is a specialty healthcare company focused on ophthalmic pharmaceuticals, drug delivery technologies, and diagnostic systems. The company operates two primary segments: pharmaceutical research and development (R&D) and ophthalmic instrumentation. In 2008, OPKO expanded its portfolio through the acquisition of Vidus Ocular, Inc. (developer of the Aquashunt glaucoma device) and secured exclusive rights to several drug candidates, including budesonide and Doxovir. The company is currently in a pre-revenue stage for its pharmaceutical pipeline, relying on its instrumentation business for limited revenue generation.

Key Financial Metrics

Note: The 2007 operating loss included a one-time non-cash charge of $243.8 million for the write-off of acquired in-process research and development (IPR&D) from the Acuity Pharmaceuticals acquisition.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased significantly from $0.8 million in 2007 to $9.4 million in 2008. This growth is attributed to the full-year inclusion of the Ophthalmic Technologies, Inc. (OTI) instrumentation business, which was acquired in late 2007. Sales were primarily international.
• Operating Expenses: Research and Development (R&D) expenses doubled to $21.6 million in 2008 from $10.9 million in 2007, driven by the Phase III clinical trial for bevasiranib. Selling, General, and Administrative (SG&A) expenses rose to $14.8 million due to increased personnel costs and equity-based compensation.
• Acquisition Activity: In May 2008, OPKO acquired Vidus Ocular, Inc., resulting in a $1.4 million immediate expense for acquired IPR&D. This contrasts with the massive $243.8 million IPR&D write-off recorded in 2007 related to the Acuity acquisition.
• Liquidity: Cash and cash equivalents decreased from $23.4 million to $6.7 million, reflecting cash burn from operations and the repayment of a $4.0 million term loan in early 2008.

Guidance, Outlook, and Risks

Clinical Trial Termination: On March 6, 2009, following the recommendation of the Independent Data Monitoring Committee (IDMC), OPKO terminated the Phase III clinical trial of bevasiranib, its most advanced product candidate for Wet AMD. The IDMC determined the trial was unlikely to meet its primary endpoint. The company anticipates an additional charge of approximately $2.4 million in Q1 2009 related to the shutdown of this trial.

Liquidity and Funding: The company expects to incur substantial losses in the foreseeable future. As of the filing date, OPKO had secured a $20 million investment from the Frost Gamma Investments Trust (announced February 2009) and a $3 million bridge loan, providing sufficient liquidity for approximately 12 months. Future funding will likely require additional equity or debt offerings, which may result in dilution.

Key Risks:

• Regulatory and Clinical Risk: Failure of clinical trials (as seen with bevasiranib) and the uncertainty of FDA approval for all product candidates.
• Manufacturing Compliance: The company received an FDA warning letter in March 2008 regarding quality control deficiencies at its Toronto facility. While a re-inspection in January 2009 found no new deficiencies, future compliance issues could halt production.
• Legal Proceedings: OPKO is defending against a lawsuit filed by Ophthalmic Imaging Systems (OIS) seeking damages in excess of $7 million (with potential ongoing damages calculated up to $28.6 million). Trial is scheduled for April 2009.
• Concentration of Ownership: The Frost Group controls a significant majority of the company's voting securities, which may influence corporate decisions.

Investor Verification Checklist

• Bevasiranib Data Analysis: Verify the company's evaluation of the terminated Phase III trial data and the feasibility of the proposed "adjunctive" use strategy with Lucentis.
• Liquidity Runway: Confirm the closing of the $20 million Frost Gamma Trust investment and the sufficiency of cash reserves to fund operations through 2010 without further dilution.
• Legal Exposure: Monitor the outcome of the OIS litigation scheduled for April 2009 and assess potential financial impact.
• Instrumentation Revenue: Track the progress of U.S. sales for the Spectral OCT SLO device following FDA 510(k) clearance received in late 2008.
• Debt Covenants: Review the terms of the $12 million related-party line of credit, which matures in January 2011 with an 11% interest rate.